Go Green This New Year - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Go Green This New Year


Pharmaceutical Technology


Angie Drakulich
As we get ready to head into the new year, chief executive and financial officers may be making their wish lists for 2008. Grow revenue. Increase pipeline. Establish new facility abroad. Acquire small-sized generics company. And so forth. But why not add something "green" to the list?Why not consider ways to help the environment while aiming for success?

Several companies are already on board. Take Cardinal Health, which is expanding its Dublin, Ohio, headquarters to house the company's Healthcare Supply Chain Services sector. The new facility is up for Leadership in Energy and Environmental Design (LEED)certification—and if approved, will be the first in Dublin to receive the honor. A project of the USGreen Building Council, LEED provides nationally accepted benchmarks for high-performance green buildings. More than 1050buildings in the US, and 1120 worldwide, have been LEED certified, meaning they meet certain sustainable development, water savings, energy efficiency, materials selection, and indoor environmental quality standards.

On the processing side, Materia (Pasadena, CA) has licensed its metathesis platform to Merck (Whitehouse Station, NJ), Aileron Therapeutics (Cambridge, MA), and Eisai (Tokyo) during the past year. Materia's catalysts help to synthesize potential new drugs with fewer byproducts and less hazardous waste.

College students are also getting into the green game. With the help of USEnvironmental Protection Agency grants, New Jersey's Rowan University is working with Bristol-Myers Squibb (BMS) (New York) and Novartis (Basel, Switzerland) to develop green engineering designs and practices. The BMS group is specifically looking at a solvent pervaporation project that could reduce carbon dioxide emissions and cut costs.

So here's to becoming a follower and a leader at the same time. Add "go green"to your comany's list of New Year's resolutions.









Angie Drakulich is the managing editor of Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here